Trauma, Hemorrhage
Conditions
Keywords
hemorrhagic shock, trauma, calcium gluconate, vasopressin
Brief summary
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
Detailed description
Resuscitation strategies for the acutely injured patient in hemorrhagic shock have evolved. Patients benefit from receiving less crystalloid in favor of blood transfusions with balanced ratios of plasma and platelets or whole blood resuscitation. These resuscitation practices are termed Damage Control Resuscitation and have been incorporated into resuscitation protocols in Level I trauma centers across the country. Damage Control Resuscitation represents standard practice for military and civilian trauma. Despite these changes, deaths from traumatic hemorrhage continue to occur in the first hours following trauma center arrival, underscoring the importance of early, novel interventions. Hypocalcemia following traumatic injury is exceedingly common following severe traumatic injury in patients at risk of hemorrhagic shock. During hemorrhagic shock resuscitation, pathways reliant upon calcium such as platelet function, intrinsic and extrinsic hemostasis, and cardiac contractility are disrupted. Citrate containing transfusion products are known to further reduce calcium levels through chelation during trauma resuscitation. Hypocalcemia has consistently been shown to be independently associated with the risk of large volume blood transfusion and mortality. Current management practices include calcium replacement during the in hospital phase of care in patients receiving blood products. Early calcium replacement in patients at risk of hemorrhage and hypocalcemia may mitigate coagulopathy, maintain hemostasis, improve hemodynamics and outcomes, and may reduce complications attributable to hemorrhagic shock. Arginine vasopressin is a physiologic hormone released by the posterior pituitary in response to hypotension and is commonly used as a vasopressor for critically ill patients for the treatment of hypotension due to multiple causes including sepsis. Prolonged hemorrhagic shock has the potential to alter systemic vasomotor tone which can progress to refractory/recalcitrant hypotension. Patients receiving resuscitation for hemorrhage are at risk of vasopressin deficiency. Vasopressin may improve hemostasis by enhancing platelet function and augmenting clot formation. Vasopressin infusion soon after injury in patients in hemorrhagic shock has been demonstrated to be safe and result in a reduction in blood transfusion requirements and a lower incidence of deep venous thrombosis. Whole blood, red cells, and blood components are a precious and limited resource. Trauma resuscitation adjuncts such as early calcium and vasopressin may provide benefit when transfusion products are limited and may provide additional benefit even when transfusion capabilities remain robust. Due to their action on coagulation and hemodynamic cascades in the injured patient, these resuscitation adjuncts have the potential to interact and provide additive benefit to the injured patient. However, safety and efficacy of prehospital calcium and early in hospital vasopressin remain inadequately characterized. Enrolled patients may participate in the prehospital phase (calcium), in-hospital phase (vasopressin), or both. The aims of the CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) trial are to determine the efficacy and safety of prehospital calcium supplementation and early in hospital vasopressin infusion as compared to standard care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize any additive effect of both resuscitation adjunct interventions.
Interventions
1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
DRUGVasopressin
4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
DRUGsaline placebo
saline placebo volume matched to prehospital or in hospital phase
Sponsors
Jason Sperry
United States Department of Defense
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
In-Hospital phase: permuted block design
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Prehospital Phase: Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating CAVALIER trial site who meet the following criteria: 1A. Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital, or during anticipated transport to a participating CAVALIER trial site OR 1B. Systolic blood pressure ≤ 70mmHg at scene, at outside hospital, or during anticipated transport to a participating CAVALIER trial site Early In-Hospital Phase: Injured patients at a participating CAVALIER trial site at risk of hemorrhagic shock who meet the following criteria: 1A. Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital, during transport, or in emergency department of a participating CAVALIER trial site OR 1B. Systolic blood pressure ≤ 70mmHg at scene, at outside hospital, during transport, or in emergency department of a participating CAVALIER trial site AND 2.Blood/blood component transfusion initiated in prehospital setting or deemed clinically indicated within 60 minutes of arrival at the enrolling trauma center AND 3. Clinical team deems Operating Room for major hemorrhage control procedure (e.g., laparotomy, thoracotomy, vascular exploration or extremity amputation) indicated within 60 minutes of arrival at the enrolling trauma center AND 4\. Anticipated admission to intensive care unit (ICU)
Exclusion criteria
Prehospital Phase 1. Wearing NO CAVALIER opt-out bracelet 2. Age \> 90 or \< 18 years of age 3. Isolated fall from standing injury mechanism 4. Known prisoner 5. Known pregnancy 6. Traumatic arrest with \> 5 minutes of CPR without return of vital signs 7. Brain matter exposed or penetrating brain injury 8. Isolated drowning or hanging victims 9. Objection to study voiced by subject or family member at the scene or at the trauma center 10. Inability to obtain IV/IO access Early In-Hospital Phase: 1. Wearing NO CAVALIER opt-out bracelet 2. Age \> 90 or \< 18 years of age 3. Isolated fall from standing injury mechanism 4. Known prisoner 5. Known pregnancy 6. Traumatic arrest with \> 5 minutes of CPR without return of vital signs 7. Brain matter exposed or penetrating brain injury 8. Isolated drowning or hanging victims 9. Objection to study voiced by subject or family member at the scene or at the trauma center 10. Inability to obtain IV access
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with 30-day mortality | from randomization to death or 30 days, whichever comes first | all cause mortality within 30 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with 6-hour mortality | from randomization to death or 6 hours, whichever comes first | all cause mortality within 6 hours |
| Number of participants with 24-hour mortality | from randomization to death or 24 hours, whichever comes first | all cause mortality within 24 hours |
| Number of participants with In-hospital mortality | In hospital mortality from time of randomization to death or 30 days, whichever comes first | death prior to hospital discharge |
| Number of participants with Death from hemorrhage | from randomization to death or 30 days, whichever comes first | Death from hemorrhage adjudicated by the site investigator |
| Number of participants with Death from brain injury | from randomization to death or 30 days, whichever comes first | Death from brain injury adjudicated by the site investigator |
| Blood and blood component transfusion requirements in the initial 6 hours | from randomization to 6 hours | number of units transfused and type |
| Blood and blood component transfusion requirements in the initial 24 hours | from randomization to 24 hours | number of units transfused and type |
| Incidence of Multiple Organ Failure (MOF) | Scores determined daily until up to Day 7 or ICU discharge, whichever comes first | Evaluated via the Denver Post injury Multiple Organ Failure Score, characterized as an incidence rate (percentage) and as MOF free days. Patients never admitted to ICU or with length of stay less than 48 hours will have a score of 0. A summary Denver score of \>3 will be classified as MOF. |
| Incidence of nosocomial infection | from randomization to death or 30 days | Utilizing the CDC criteria for diagnosis of hospital acquired pneumonia and blood stream infection |
| Time to hemostasis | hospital arrival to 4 hours | Determined by ability to reach nadir transfusion requirement of 1 unit of red blood cells in a 60 minute period in the first 4 hours following arrival. In the absence of ability to obtain hemostasis within the first 4 hours, the patient will be designated "non-hemostasis" |
| Incidence of coagulopathy by thromboelastography (TEG) | within 4 hours of arrival plus or minus 12 | TEG date collected only when obtained as part of clinical |
| ICU free days | From hospital arrival to death or 30 days | number of days the patient is alive and not admitted to ICU subtracted from 30 |
| Hospital free days | From hospital arrival to death or 30 days | number of days the patient is alive and not admitted to hospital subtracted from 30 |
| Ionized calcium measurements | Measured in the first 60 minutes (+/- 3 hours), when feasible, during early stage resuscitation in emergency department or operating room | Ionized calcium collected as part of clinical care or as research lab |
Countries
United States
Contacts
CONTACTJason Sperry, MD
PRINCIPAL_INVESTIGATORJason Sperry, MD
University of Pittsburgh
Outcome results
None listed